With approved or close to being approved product, getting to market seems a lot harder for management, ticking all the right boxes
Biotech companies are very under valued in the Australian market, until they show revenue or big Big Pharmaceutical interest for products they seem to remain small caps, buying and selling for scraps
With approved or close to being approved product, getting to...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.005(1.39%) |
Mkt cap ! $76.40M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $2.864K | 7.871K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 136618 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 4400 | 1 |
View Market Depth
| Last trade - 15.53pm 26/06/2024 (20 minute delay) ? |
| OCC (ASX) Chart |